News FDA turns down Hetlioz for jet lag once again Vanda will continue to push for approval of Hetlioz for jet lag, despite the FDA saying its trial designs were not satisfactory.
News Lundbeck bows out of bidding war for Avadel Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.
News Lundbeck makes bid for Avadel, trying to displace Alkermes Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.
News Alkermes breaks new ground in narcolepsy with orexin drug Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.
News Court sides with Vanda over FDA's Hetlioz rejection A court has ordered the FDA to revisit a decision to turn down a drug for jet lag developed by Vanda, potentially setting a crucial legal precedent.
News Algorithm spots common sleep disorder linked to dementia An AI algorithm can help detect REM sleep behaviour disorder, which affects millions of people and is a warning signal for neurological diseases.
News Nature: "Sidewinder" tech a leap forward in DNA synthesis A new technology developed at Cal-Tech represents a breakthrough in DNA synthesis, essentially allowing de novo sequence creation.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
